Premium
PHASE IB STUDY OF CC‐122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMAS (NHL)
Author(s) -
Michot J.M.,
Bouabdallah R.,
Doorduijn J.K.,
Vitolo U.,
Chiappella A.,
Kersten M.J.,
Zinzani P.L.,
Sarmiento R.,
Mosulen S.,
Petrarca M.,
Pourdehnad M.,
Hege K.,
Yang Z.,
Nikolova Z.,
Ribrag V.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_37
Subject(s) - medicine , obinutuzumab , neutropenia , tolerability , gastroenterology , rituximab , febrile neutropenia , lymphoma , phases of clinical research , oncology , adverse effect , toxicity